JP2004516293A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004516293A5 JP2004516293A5 JP2002551564A JP2002551564A JP2004516293A5 JP 2004516293 A5 JP2004516293 A5 JP 2004516293A5 JP 2002551564 A JP2002551564 A JP 2002551564A JP 2002551564 A JP2002551564 A JP 2002551564A JP 2004516293 A5 JP2004516293 A5 JP 2004516293A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- phenyl
- conh
- propyl
- butyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 77
- 150000001875 compounds Chemical class 0.000 description 20
- 239000000556 agonist Substances 0.000 description 15
- 229910052731 fluorine Inorganic materials 0.000 description 15
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 12
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 12
- 239000003814 drug Substances 0.000 description 10
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 8
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 8
- 125000002947 alkylene group Chemical group 0.000 description 7
- -1 CF 3 Inorganic materials 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 4
- 239000011737 fluorine Substances 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 229940086609 Lipase inhibitor Drugs 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 2
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
- 102000004146 ATP citrate synthases Human genes 0.000 description 1
- 108090000662 ATP citrate synthases Proteins 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 229940122816 Amylase inhibitor Drugs 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 102000013585 Bombesin Human genes 0.000 description 1
- 108010051479 Bombesin Proteins 0.000 description 1
- 102000019432 Galanin Human genes 0.000 description 1
- 101800002068 Galanin Proteins 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- 102000057248 Lipoprotein(a) Human genes 0.000 description 1
- 108010033266 Lipoprotein(a) Proteins 0.000 description 1
- 229940122014 Lyase inhibitor Drugs 0.000 description 1
- 229940124757 MC-4 agonist Drugs 0.000 description 1
- 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 description 1
- 102000002512 Orexin Human genes 0.000 description 1
- 102000000536 PPAR gamma Human genes 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 229940124754 PPAR-alpha/gamma agonist Drugs 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 229940123495 Squalene synthetase inhibitor Drugs 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 102000005630 Urocortins Human genes 0.000 description 1
- 108010059705 Urocortins Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 239000003392 amylase inhibitor Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 229940125388 beta agonist Drugs 0.000 description 1
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 description 1
- 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000002697 lyase inhibitor Substances 0.000 description 1
- 229950004994 meglitinide Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 108060005714 orexin Proteins 0.000 description 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000000952 serotonin receptor agonist Substances 0.000 description 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 230000002295 serotoninergic effect Effects 0.000 description 1
- 239000004059 squalene synthase inhibitor Substances 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 239000000777 urocortin Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10064402A DE10064402A1 (de) | 2000-12-21 | 2000-12-21 | Diphenylazetidinonderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| DE2001154520 DE10154520A1 (de) | 2001-11-07 | 2001-11-07 | Diphenylazetidinonderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| PCT/EP2001/014532 WO2002050068A1 (de) | 2000-12-21 | 2001-12-11 | Diphenylazetidinonderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004516293A JP2004516293A (ja) | 2004-06-03 |
| JP2004516293A5 true JP2004516293A5 (enExample) | 2006-01-05 |
Family
ID=26008045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002551564A Abandoned JP2004516293A (ja) | 2000-12-21 | 2001-12-11 | ジフェニルアゼチジノン誘導体、その製造方法、これらの化合物を含む医薬およびその使用 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US6498156B2 (enExample) |
| EP (1) | EP1345932B1 (enExample) |
| JP (1) | JP2004516293A (enExample) |
| KR (1) | KR20030061462A (enExample) |
| CN (1) | CN1222522C (enExample) |
| AR (1) | AR034282A1 (enExample) |
| AT (1) | ATE342899T1 (enExample) |
| AU (2) | AU2002219173B2 (enExample) |
| BR (1) | BR0116482A (enExample) |
| CA (1) | CA2431985A1 (enExample) |
| CZ (1) | CZ20031731A3 (enExample) |
| DE (1) | DE50111293D1 (enExample) |
| EE (1) | EE200300237A (enExample) |
| HR (1) | HRP20030499A2 (enExample) |
| HU (1) | HUP0401067A2 (enExample) |
| IL (1) | IL156552A0 (enExample) |
| MX (1) | MXPA03005018A (enExample) |
| NO (1) | NO20032733L (enExample) |
| NZ (1) | NZ526592A (enExample) |
| PL (1) | PL362173A1 (enExample) |
| SK (1) | SK7812003A3 (enExample) |
| WO (1) | WO2002050068A1 (enExample) |
| YU (1) | YU46903A (enExample) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| MXPA03005155A (es) * | 2000-12-21 | 2003-09-10 | Aventis Pharma Gmbh | 1,2-difenilazetidinonas novedosas, procesos para su preparacion, farmacos que contienen compuestos y su uso para el tratamiento del metabolismo afectado de los lipidos. |
| ATE331512T1 (de) | 2001-01-26 | 2006-07-15 | Schering Corp | Verwendung azetidinone-substituierter verbindungen zur behandlung der sitosterolhämie |
| HU230253B1 (hu) * | 2001-01-26 | 2015-11-30 | Merck Sharp & Dohme Corp | Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére |
| KR20080077033A (ko) * | 2001-01-26 | 2008-08-20 | 쉐링 코포레이션 | 혈관 질환을 치료하기 위한 스테롤 흡수 억제제와 심혈관제제의 조합물 |
| IL156488A0 (en) * | 2001-01-26 | 2004-01-04 | Schering Corp | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions |
| AR034204A1 (es) * | 2001-01-26 | 2004-02-04 | Schering Corp | Composiciones y combinaciones de acido nicotinico y derivados del mismo con inhibidor(es) de la absorcion de los esteroles, y el uso de los mismos para preparar medicamentos para el tratamiento para indicaciones vasculares |
| AR035739A1 (es) * | 2001-01-26 | 2004-07-07 | Schering Corp | Composiciones farmaceuticas y combinaciones terapeuticas que comprenden secuestrante (s) de los acidos biliares y de inhibidor (es) de la absorcion de los esteroles y el uso de dichas composiciones para la manufactura de un medicamento para el tratamiento de indicaciones vasculares |
| US7071181B2 (en) | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
| CN1655792A (zh) * | 2001-08-22 | 2005-08-17 | 安万特医药德国有限公司 | 1,4－苯并硫杂䓬－1,1－二氧化物衍生物与其它活性成分的组合产物及其用途 |
| US7053080B2 (en) | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| US7056906B2 (en) | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
| EP1429756B1 (en) | 2001-09-21 | 2006-11-22 | Schering Corporation | Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors |
| US20030119808A1 (en) * | 2001-09-21 | 2003-06-26 | Schering Corporation | Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects |
| US7176194B2 (en) | 2002-06-19 | 2007-02-13 | Sanofi-Aventis Deutschland Gmbh | Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use |
| DE10227507A1 (de) * | 2002-06-19 | 2004-01-08 | Aventis Pharma Deutschland Gmbh | Kationisch substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| DE10227508A1 (de) * | 2002-06-19 | 2004-01-08 | Aventis Pharma Deutschland Gmbh | Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| US7176193B2 (en) | 2002-06-19 | 2007-02-13 | Sanofi-Aventis Deutschland Gmbh | Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use |
| US7671047B2 (en) | 2002-06-19 | 2010-03-02 | Sanofi-Aventis Deutschland Gmbh | Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use |
| GB0215579D0 (en) * | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
| CN1678296A (zh) * | 2002-07-30 | 2005-10-05 | 卡里凯昂公司 | 依泽替米贝的组合物和治疗胆固醇有关的良性与恶性肿瘤的方法 |
| JP2006508189A (ja) | 2002-11-06 | 2006-03-09 | シェーリング コーポレイション | 自己免疫障害の処置のためのコレステロール吸収インヒビター |
| DE602004016123D1 (de) | 2003-03-07 | 2008-10-09 | Schering Corp | Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia |
| US7192944B2 (en) | 2003-03-07 | 2007-03-20 | Schering Corp. | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| US7459442B2 (en) | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| JP4589919B2 (ja) | 2003-03-07 | 2010-12-01 | シェーリング コーポレイション | 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用 |
| JP5172146B2 (ja) * | 2003-05-09 | 2013-03-27 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | 癌を標的化するための組成物及び方法 |
| EP1660456A2 (en) * | 2003-08-25 | 2006-05-31 | Microbia Inc. | Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones |
| US8987322B2 (en) * | 2003-11-04 | 2015-03-24 | Circ Pharma Research And Development Limited | Pharmaceutical formulations for carrier-mediated transport statins and uses thereof |
| EP1918000A2 (en) | 2003-11-05 | 2008-05-07 | Schering Corporation | Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions |
| EP1699759B1 (en) | 2003-12-23 | 2010-10-20 | AstraZeneca AB | Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity |
| WO2005067903A1 (en) * | 2004-01-20 | 2005-07-28 | Panacea Biotec Ltd. | Pharmaceutical compositions comprising higher primary alcohols and ezetimibe and process of preparation thereof |
| HRP20130115T4 (hr) | 2004-03-05 | 2016-04-22 | The Trustees Of The University Of Pennsylvania | Postupci liječenja poremećaja ili bolesti povezanih sa hiperlipidemijom i hiperkolesterolemijom uz minimizaciju sporednih efekata |
| CA2581596A1 (en) * | 2004-09-29 | 2006-04-13 | Schering Corporation | Combinations of substituted azetidonones and cb1 antagonists |
| CA2580690A1 (en) * | 2004-10-21 | 2006-05-04 | Transtech Pharma, Inc. | Bissulfonamide compounds as agonists of galr1, compositions, and methods of use |
| AU2005311930B9 (en) | 2004-12-03 | 2009-09-10 | Merck Sharp & Dohme Corp. | Substituted piperazines as CB1 antagonists |
| TW200726746A (en) * | 2005-05-06 | 2007-07-16 | Microbia Inc | Processes for production of 4-biphenylylazetidin-2-ones |
| JP2008543744A (ja) * | 2005-05-09 | 2008-12-04 | マイクロビア インコーポレーテッド | 有機金属ベンゼンホスホナートカップリング剤 |
| WO2006122216A2 (en) * | 2005-05-11 | 2006-11-16 | Microbia, Inc. | Processes for production of phenolic 4-biphenylylazetidin-2-ones |
| EA200702614A1 (ru) * | 2005-05-25 | 2008-04-28 | Майкробиа, Инк. | Способы получения 4-(бифенилил)азетидин-2-оналкилфосфиновых кислот |
| DE602006010870D1 (de) * | 2005-06-20 | 2010-01-14 | Schering Corp | Als antagonisten von histamin h3 geeignete piperidinderivate |
| SA06270191B1 (ar) | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
| EP1951224A2 (en) * | 2005-10-18 | 2008-08-06 | Aegerion Pharmaceuticals | Methods for treating disorders associated with hyperlipidemia in a mammal |
| RU2008133381A (ru) * | 2006-01-18 | 2010-02-27 | Шеринг Корпорейшн (US) | Модуляторы каннабиноидного рецептора |
| TW200811098A (en) | 2006-04-27 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
| WO2008017381A1 (de) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung |
| CA2661404A1 (en) * | 2006-09-05 | 2008-03-13 | Schering Corporation | Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis |
| WO2008039829A2 (en) * | 2006-09-26 | 2008-04-03 | Ironwood Pharmaceuticals, Inc. | Diphenylheterocycle cholesterol absorption inhibitors |
| DE102007002260A1 (de) | 2007-01-16 | 2008-07-31 | Sanofi-Aventis | Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms |
| WO2008130616A2 (en) * | 2007-04-19 | 2008-10-30 | Schering Corporation | Diaryl morpholines as cb1 modulators |
| US20100286160A1 (en) * | 2007-06-28 | 2010-11-11 | Intervet Inc. | Substituted piperazines as cb1 antagonists |
| BRPI0814806A2 (pt) * | 2007-06-28 | 2015-02-03 | Intervet Int Bv | Pirazinas substituídas como antagonistas de cb1 |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE102007063671A1 (de) | 2007-11-13 | 2009-06-25 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| US20090312302A1 (en) * | 2008-06-17 | 2009-12-17 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders |
| EP2310372B1 (en) | 2008-07-09 | 2012-05-23 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| CA2754384A1 (en) | 2009-03-06 | 2010-09-10 | Lipideon Biotechnology Ag | Pharmaceutical hypocholesterolemic compositions |
| CN101993403B (zh) | 2009-08-11 | 2012-07-11 | 浙江海正药业股份有限公司 | 氮杂环丁酮类化合物及医药应用 |
| DK2470552T3 (en) | 2009-08-26 | 2014-02-17 | Sanofi Sa | NOVEL, CRYSTALLINE, heteroaromatic FLUORGLYCOSIDHYDRATER, MEDICINES COVERING THESE COMPOUNDS AND THEIR USE |
| WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| EP2683700B1 (de) | 2011-03-08 | 2015-02-18 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| CN102746249B (zh) * | 2012-07-07 | 2013-12-25 | 山东诚创医药技术开发有限公司 | 一种依折麦布中间体的纯化精制方法 |
| JP2023536855A (ja) | 2020-07-29 | 2023-08-30 | アムリット・ファーマシューティカルズ・インコーポレイテッド | 小児患者における高脂血症及び高コレステロール血症の治療方法における使用のためのロミタピド |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5631365A (en) * | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| CA2191455A1 (en) * | 1994-06-20 | 1995-12-28 | Wayne Vaccaro | Substituted azetidinone compounds useful as hypocholesterolemic agents |
| DE69520364T2 (de) * | 1994-09-13 | 2001-09-13 | Monsanto Company, St. Louis | Benzothepines mit wirkung als inhibitoren des gallensäuretransports und der taurocholate-aufnahme |
| US5994391A (en) * | 1994-09-13 | 1999-11-30 | G.D. Searle And Company | Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| US5656624A (en) * | 1994-12-21 | 1997-08-12 | Schering Corporation | 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents |
| US5756470A (en) | 1996-10-29 | 1998-05-26 | Schering Corporation | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
-
2000
- 2000-12-11 IL IL15655200A patent/IL156552A0/xx unknown
-
2001
- 2001-12-11 YU YU46903A patent/YU46903A/sh unknown
- 2001-12-11 CZ CZ20031731A patent/CZ20031731A3/cs unknown
- 2001-12-11 AU AU2002219173A patent/AU2002219173B2/en not_active Expired - Fee Related
- 2001-12-11 BR BR0116482-1A patent/BR0116482A/pt not_active IP Right Cessation
- 2001-12-11 CA CA002431985A patent/CA2431985A1/en not_active Abandoned
- 2001-12-11 WO PCT/EP2001/014532 patent/WO2002050068A1/de not_active Ceased
- 2001-12-11 SK SK781-2003A patent/SK7812003A3/sk unknown
- 2001-12-11 KR KR10-2003-7008330A patent/KR20030061462A/ko not_active Withdrawn
- 2001-12-11 MX MXPA03005018A patent/MXPA03005018A/es active IP Right Grant
- 2001-12-11 AT AT01271371T patent/ATE342899T1/de not_active IP Right Cessation
- 2001-12-11 DE DE50111293T patent/DE50111293D1/de not_active Expired - Lifetime
- 2001-12-11 PL PL01362173A patent/PL362173A1/xx not_active Application Discontinuation
- 2001-12-11 AU AU1917302A patent/AU1917302A/xx active Pending
- 2001-12-11 JP JP2002551564A patent/JP2004516293A/ja not_active Abandoned
- 2001-12-11 CN CNB018210449A patent/CN1222522C/zh not_active Expired - Fee Related
- 2001-12-11 NZ NZ526592A patent/NZ526592A/en unknown
- 2001-12-11 HR HR20030499A patent/HRP20030499A2/hr not_active Application Discontinuation
- 2001-12-11 HU HU0401067A patent/HUP0401067A2/hu unknown
- 2001-12-11 EP EP01271371A patent/EP1345932B1/de not_active Expired - Lifetime
- 2001-12-11 EE EEP200300237A patent/EE200300237A/xx unknown
- 2001-12-19 US US10/021,028 patent/US6498156B2/en not_active Expired - Lifetime
- 2001-12-19 AR ARP010105906A patent/AR034282A1/es unknown
-
2003
- 2003-06-16 NO NO20032733A patent/NO20032733L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004516293A5 (enExample) | ||
| JP2005533073A5 (enExample) | ||
| JP2005533071A5 (enExample) | ||
| JP2008524127A5 (enExample) | ||
| FR20C1018I1 (fr) | Composition pharmaceutique comprenant du glycopyrrolate et un agoniste du récepteur beta2 adrénergique | |
| JP2005533072A5 (enExample) | ||
| JP2006502247A5 (enExample) | ||
| GB9524157D0 (en) | Therapeutic agents | |
| RU2005101093A (ru) | Замещенные кислотными группами дифенилазетидиноны, способ их получения, содержащие эти соединения лекарственных средства, и их применение | |
| JP2005511698A5 (enExample) | ||
| AU2003255668A8 (en) | Arylsulphonamide derivatives and use thereof as b1 bradykinin receptor antagonists | |
| NZ515282A (en) | Substituted phenyl compounds with immunosuppressing activity and pharmaceutical compositions | |
| EA200000155A2 (ru) | 4-фенилпиридиновые производные | |
| DK0775129T3 (da) | 3-Benzoylbenzofuranderivater som thyroidhormonantagonister | |
| RU2007138584A (ru) | Соединения, обладающие активностью для коррекции процессинга мутантного cftr, и их применение | |
| MY124864A (en) | Adenosine a2a receptor antagonists | |
| DE69402981D1 (de) | 3,5-dioxo-(2h,4h)-1,2,4-triazine als 5ht1a ligande | |
| RU2005101088A (ru) | Катионозамещенные дифенилазетидиноны, способ их получения, лекарственные средства, содержащие эти соединения, и их применение | |
| RU2007101309A (ru) | Боросодержащее соединение и способы применения | |
| RU2394031C2 (ru) | Соли четвертичного аммония в качестве антагонистов м3 | |
| EA200501703A1 (ru) | Применение производных азетидинкарбоксамида в терапии | |
| DE60324685D1 (de) | 2-(phenylthiomethyl)- morpholin-derivate zur verwendung als selektive norepinephrin-wiederaufnahme-inhibitoren | |
| SE0203303D0 (sv) | Novel Compounds | |
| JP2005532402A5 (enExample) | ||
| SE0203302D0 (sv) | Novel Compounds |